MONROVIA, Calif. and HANGZHOU, China, Oct. 16 /PRNewswire-FirstCall/-- Niusule Biotech Corp. (“Niusule” or the “Company”) (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company has entered into a
“We are pleased to announce that we have entered into a supply agreement with a reputed nutritional supplement manufacturer in the U.S.,” commented Ms. Qinghua Hu, CEO and CFO of Niusule Biotech Corp. “We believe securing a reliable and stable supply of high-quality products is an important step, especially in light of our recent expansion into China and the growing demand for gummy bears and other nutritional products in the Chinese market. We are excited about this opportunity and are confident in our ability to further expand our business and increase profitability.”
About Niusule Biotech Corp.
Niusule is engaged in the business of manufacturing, marketing and selling health food and related products. The Company manufactures mature health food products, including PlantFusion and Gummy Bears, in the United States and markets and distributes these products to Chinese consumers. Niusule also maintains a strong focus on biotechnology R&D and is committed to becoming a leading player in China’s rapidly growing health food and bioengineering industry. The Company’s products are cultivated from natural plants and improved in flavors through R&D program with the Zhejiang University in China. Niusule’s products are manufactured in strict accordance with international standards. For more information, contact CCG Investor Relations directly or go to Niusule’s website at http://www.niusule.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. You are urged to consider these factors care in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
SOURCE Niusule Biotech Corp.
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All